Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Darren M. Kocs,R. N. Raju,M. A. Socinski,Thomas E. Stinchcombe,Steven R. Rousey,David Barrera,Yue wang,Jane L. Bromund,Joseph Treat,Coleman K. Obasaju

Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

2008

Darren M. Kocs
R. N. Raju
M. A. Socinski
Thomas E. Stinchcombe
Steven R. Rousey
David Barrera
Yue wang
Jane L. Bromund
Joseph Treat
Coleman K. Obasaju

8037 Background: E is a selective, oral serine/threonine kinase inhibitor. The combination of PCb has shown clinical activity in two phase 2 trials of advanced NSCLC. A phase 3 trial among pts with...

Keywords:

Carboplatin
non-small cell lung cancer (NSCLC)
Physical therapy
Pemetrexed
Enzastaurin
Cancer research
Oncology
Medicine
Internal medicine
Docetaxel
first line treatment
stage iiib
Kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations